Nuvectis reports Q3 2026 results, advances ciprocopan and NXP200 toward US filings
Nuvectis says FDA talks on ciprocopan for PNH are underway with an update expected by year-end, as it plans US IND filings for both lead oncology and complement assets.
SEC filing